Electric vehicle charging stocks are on fire today on Biden infrastructure plan

Electric vehicle charging stocks are on fire today on Biden infrastructure plan

Shares of Chargepoint (CHPT) were up 15.40% as of 2:30 p.m. New York time today, March 31. Charging station competitor Blink Charging (BLNK) was up 8.69%. The big jump came on speculation that the Biden administration’s infrastructure plan with its emphasis on growing the number of electric vehicles in use would include incentives and money for expanding the woefully inadequate U.S. network of charging stations for electric cars.

Dip-O-Meter update for March 29–taking a very modest bite of buy on the dip with three picks

Dip-O-Meter update for March 29–taking a very modest bite of buy on the dip with three picks

I’ve scrubbed through the 20 stocks in the Dip-O-Meter, with updated numbers as of the close on Friday, March 26, looking for the best three buy on the dip trades. (Why only three? Because I think the same volatility that has created these profit opportunities makes it hard to be certain of a trend and I don’t want to bet the farm with the current degree of uncertainty. My choices for trades that I’ll put on tomorrow in my Volatility Portfolio are SunRun (RUN), Teladoc (TDOC), and PayPal (PYPL). These are all going into my Volatility Portfolio

Business as usual today March 22–tech stocks rebound–except…which is why I’m buying more VIX options tomorrow

Business as usual today March 22–tech stocks rebound–except…which is why I’m buying more VIX options tomorrow

You’ve read this story before (in fact many times before) in the last month or so. Tech stocks rebounded after a day or two of selling. What was different (because it wasn’t a case of rotation but a continuation of a recent trend) was the continued drop in the CBOE S&P 500 Volatility Index (VIX) to 18.88, a decrease of 9.88%

Special Reports: Profit and Protect–What you need to know about stock market stages for 2021–my first two hedges (copper and banks) for Stage #2

Hedges that can pay off on the downside and the upside are the most useful and most valuable. They also tend to be relatively rare. There aren’t a lot of these bets floating around in most markets just waiting for you to snap them up. However, I have found two hedges of just this sort in today’s market that I’m going to recommend to you today. (In this post I’m going to give you some of the nitty gritty numbers that support my recommendation for these two hedges. If you want to see some charts for copper and gold, banks and bonds check out the video I posted today.) I’m going to add these new recommendations to my standing Special Reports post tomorrow.

So what’s the matter with Incyte stock? Just about nothing although you wouldn’t know it from the recent price movement

So what’s the matter with Incyte stock? Just about nothing although you wouldn’t know it from the recent price movement

Shares of biotech stock Incyte (INCY) have been down significantly in 2021. For the year to date, as of the close on March 2, the shares were down 8.45%. In the last month they’ve tumbled 12.42%. So what’s wrong? Pretty much nothing. With the individual stock anyway. What we’re watching is a lot of selling in the biotech sector as part of the recent sell-off on risk. And on substantial profit taking.

Special Report: Profit and Protect–What you need to know about stock market stages for 2021–Stage 2 of 3: My rules for selling in the “When you win, you lose market” (and sells of ILMN, CTVA, WST, and VMW)

Special Report: Profit and Protect–What you need to know about stock market stages for 2021–Stage 2 of 3: My rules for selling in the “When you win, you lose market” (and sells of ILMN, CTVA, WST, and VMW)

On to Stage #2 in my Special Report: “Profit and Protect–What you need to know about stock market stages for 2021. And to my rules for the sells and hedges in Stage #2 for 2021: When you win, you lose. (I just posted sells for ILMN, CTVA, WST and VMW)

Vaxart plunges on deeply disappointing vaccine trial data

Vaxart is looking like a “short-squeeze rocket”–is it?

Ok, I don’t want to see “the next GameStop under every rock.” But Vaxart (VXRT) deserves a look or two. (The stock is a member of my Volatility Portfolio where it’s up 5.27 as of the close on February 1 since I added it to the portfolio on July 22, 2020. I also own shares in my personal portfolio.) Here’s what I see with the shares of this company that is in clinical trials of a vaccine for the coronavirus. Vaxart’s vaccine is a pill and it’s the only vaccine pill under development. Shares of Vaxart are up (as of the February 1 close) 54.93% in the last week and 172.68% in the last month. They’ve added 216.46% in the last 3 months and are up 172.68% for 2021 to date as of the close on February 1. The shares moved up another 29.97% today to $15.57 a share.

Signs of a market top Part 1: Looks like a topping market to me–see TSLA, DASH, ABNB, AI for evidence

Signs of a market top Part 1: Looks like a topping market to me–see TSLA, DASH, ABNB, AI for evidence

I see all the signs of a market that’s moved beyond enthusiasm to excess. This stage in a market is called many things. A market melt. Forming a top. You get the idea. We won’t, of course, know if the current levels constitute a top until we get a sustained downturn. And waiting for that confirming downturn can take a while and be very painful if you’ve tried to time the turn with shorts or Put Options and turn out to have been early. The topping process can go on for a while.